Home » Rapid Micro Biosystems Releases Service Pack 2 Software for Growth Direct
Rapid Micro Biosystems Releases Service Pack 2 Software for Growth Direct
PharmaManufacturing.com
06/22/2010
Rapid Micro Biosystems, a company developing innovative products for faster and automated detection of microbial contamination, today announced the availability of Service Pack 2 software for the Growth Direct System. The new release includes both user and industry driven product features that enable Quality Control labs to improve their performance by optimizing workflow and eliminating waste. These capabilities will drive the transformation from manual quality control to an automated, paperless laboratory.
Increased Manufacturing Efficiency and Throughput
New alerting features let the business respond faster to key quality events, such as the early warning of contaminated product samples, improving efficiency, speeding corrective actions and preventing product loss. Other alerts ensure testing compliance, such as indicating when samples have not been properly handled. Escalation emails trigger samples that exceed an action or alert limit. Device alarms sound when quality anomalies occur.
Early notification of contamination allows the QC lab to take action earlier and prevent further product corruption. For example, taking a fermentor offline before its material is combined with other product in-process enables more productive use of plant resources and capacity. Continuous readout of microbial results prior to completion allows users to get an early view of any developing contamination issues and consult proactively with their manufacturing partners to resolve it.
Electronic access to testing results through a company’s Laboratory Information Management System (LIMS) allows key stakeholders beyond the QC lab to view testing results as they are completed, eliminating unnecessary emails, meetings, phone calls and paper. These stakeholders can then take faster remediation based upon sample results, improving their efficiency and focusing on process improvements.
Automating the Quality Control Laboratory
Service Pack 2 focuses on features to streamline workflow and eliminate waste in the QC lab. These new Growth Direct System capabilities allow pharmaceutical companies to efficiently manage their labor resources and changes in workload. For instance, users can increase laboratory testing efficiency through batch loading of samples while providing flexibility to accommodate random access sample loading.
The paperless QC lab is enabled through seamless LIMS connectivity that automates results recording, data management and reporting, a common source of errors. The system automatically archives results and history, integral to regulatory compliance and critical for traceability and audit-ability.
Custom reporting allows users to tailor reports specific to their needs. Users can easily and efficiently adjust reports to match the laboratory convention and business needs. The time saved allows the quality lab to improve efficiency, reduce errors and focus on value-added activities, critical to any Lean Laboratory program.
Rapid Micro Biosystems CEO, Steve Delity says, "Poor productivity in the Pharmaceutical industry is a significant problem. This is costing organizations millions of dollars a year that, when fixed, drop straight to the bottom line. Our enhancements to the Growth Direct™ System help companies compete in a tough global market by automating and modernizing their quality processes and detecting microbes in half the time of traditional methods. This improves manufacturing cycle-time, increases production capacity and productivity to drive quantifiable results.”
About Rapid Micro Biosystems
Rapid Micro Biosystems, a venture-backed company headquartered in Bedford, Massachusetts, provides innovative products for faster detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. The company's Growth DirectTM System, commercialized in 2008, detects contamination earlier, delivering compelling economic benefits to manufacturers while improving their quality process. The Growth DirectTM System is the first and only automated system that accelerates testing, fits with current regulatory practices, and addresses all key applications. For more information, visit www.rapidmicrobio.com.
More News:
-
02/09/2012
Watchdog Fines Ernst & Young $2 million Over Medicis Pharma Corp. AuditsFrom Reuters.com
The watchdog board for corporate auditors on Wednesday said it has imposed a $2 million penalty, its largest fine ever, on accounting and consulting firm Ernst & Young LLP in a settlement involving past audits of Medicis Pharmaceutical Corp.
-
02/09/2012
FDA Issues Draft Guidance on Biosimilar Product Development
The U.S. Food and Drug Administration today issued three draft guidance documents on biosimilar product development to assist industry in developing such products in the United States.
-
02/08/2012
Biomedical Industry Loses Momentum in California, According to 2012 Report
Innovation slows as productivity in the Biomedical industry declines
-
02/02/2012
Pfizer Baby Boom? Pfizer's Official StatementFrom Pharmalot.com
About nine months from now, a new phenomenon may appear at a hospital near you: the Pfizer baby. Why? The drugmaker has taken the embarrassing step of recalling 1 million packets of birth control pills due to a packaging error. Hear EVP and CMO, Freda Lewis-Hall's read Pfizer's official statement.
-
02/02/2012
News: AstraZeneca To Cut 7,300 JobsFrom MarketWatch.com
Drug firm AstraZeneca on Thursday said it would cut approximately 7,300 jobs as part of an ongoing initiative to reduce costs and drive innovation.
-
02/01/2012
Pfizer Recalls 1 Million Birth Control Packs for Error That Could Cause Unintended PregnancyFrom WashingtonPost.com
Pfizer Inc. is recalling 1 million packets of birth control pills due to a packaging error that could raise the risk of an accidental pregnancy by leaving women with an inadequate dose. The problem affects 14 lots of Lo/Ovral-28 tablets and 14 lots of generic Norgestrel and Ethinyl Estradiol tablets. Both products are manufactured by Pfizer and marketed in the U.S. by Akrimax Rx Products under the Akrimax Pharmaceuticals brand.
-
01/26/2012
News: Abbott Labs Cuts 700 Manufacturing JobsFrom WashingtonPost.com
Medical device and drugmaker Abbott Laboratories said Wednesday it will lay off 700 employees as part of ongoing restructuring efforts. A company spokeswoman said most of the layoffs will affect employees who manufacture the company’s heart stents and diagnostic tests.
- 01/24/2012 ISPE Announces 2012 FOYA Winners
- 01/24/2012 Genzyme Gains Approval for Framingham Site, a Boost to Fabrazyme Production
-
01/19/2012
Big Pharma Execs May Wish They'd Never Heard Of Paula DeenFrom Forbes.com
Novo Nordisk has nabbed Paula Deen as a new spokeswoman to help raise awareness about type 2 diabetes. Many in the drug industry wish it weren’t so, but without major legal and regulatory changes, such matches between celebs and drug firms are as certain as the sun rising in the east.
- All news »
Get Connected Now!
- Featured White Papers

Print page